Published in J Infect Dis on October 15, 2010
Early immunologic failure is associated with early mortality among advanced HIV-infected adults initiating antiretroviral therapy with active tuberculosis. J Infect Dis (2013) 1.00
Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine (2010) 0.99
Polyantigenic interferon-γ responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization. PLoS One (2011) 0.86
Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. Clin Infect Dis (2012) 0.84
Differences in antigen-specific CD4+ responses to opportunistic infections in HIV infection. Immun Inflamm Dis (2015) 0.80
Asymptomatic HIV-infected individuals on antiretroviral therapy exhibit impaired lung CD4(+) T-cell responses to mycobacteria. Am J Respir Crit Care Med (2014) 0.78
Greater preexisting interferon γ responses to mycobacterial antigens and lower bacillary load during HIV-associated tuberculosis. J Infect Dis (2013) 0.76
Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis. PLoS One (2016) 0.75
Pulmonary immune-compartment-specific interferon gamma responses in HIV-infected individuals with active tuberculosis (TB) in an area of high TB prevalence. Clin Dev Immunol (2012) 0.75
Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA (1994) 14.96
Variation in protection by BCG: implications of and for heterologous immunity. Lancet (1995) 9.66
Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med (2008) 9.49
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med (1997) 8.43
Global epidemiology of tuberculosis. Lancet (2006) 6.70
Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med (2008) 5.81
Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med (2004) 5.78
Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med (1996) 5.36
The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics (1995) 4.72
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis (2005) 4.45
Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis (2004) 4.26
BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet (2002) 3.75
Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med (1999) 3.45
Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J Immunol (1999) 2.94
Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis (2008) 2.64
Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med (2008) 2.36
Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol (2008) 2.27
Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. Clin Infect Dis (2007) 2.23
Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis (2009) 1.96
Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: a population-based prospective study of 301 pulmonary tuberculosis patients. J Clin Microbiol (2001) 1.80
The importance of recent infection with Mycobacterium tuberculosis in an area with high HIV prevalence: a long-term molecular epidemiological study in Northern Malawi. J Infect Dis (2005) 1.79
Counting antigen-specific T cells: a new approach for monitoring response to tuberculosis treatment? Clin Infect Dis (2004) 1.68
Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guérin. J Immunol (1997) 1.64
Increased specific T cell cytokine responses in patients with active pulmonary tuberculosis from Central Africa. Microbes Infect (2005) 1.63
Utility of the antigen-specific interferon-gamma assay for the management of tuberculosis. Curr Opin Pulm Med (2005) 1.60
Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet (2008) 1.52
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis (2008) 1.44
Utility of interferon-gamma ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South Africa. BMC Infect Dis (2007) 1.31
Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS (2006) 1.30
Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. J Infect Dis (1996) 1.21
The immune response to Mycobacterium tuberculosis in HIV-infected and uninfected adults in Uganda: application of a whole blood cytokine assay in an epidemiological study. Int J Tuberc Lung Dis (1999) 1.20
Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis (2001) 1.15
Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med (2009) 1.09
Evidence of previous infection with Mycobacterium avium-Mycobacterium intracellulare complex among healthy subjects: an international study of dominant mycobacterial skin test reactions. J Infect Dis (1993) 1.03
Cell-mediated immune responses to mycobacterial antigens in patients with pulmonary tuberculosis and HIV infection. Clin Exp Immunol (1997) 0.98
Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS (2003) 0.97
Biology of the mycobacterioses. Identification of the tuberculous-infected by skin tests. Ann N Y Acad Sci (1968) 0.96
Cellular immune responses to four doses of percutaneous bacille Calmette-Guérin in healthy adults. J Infect Dis (1998) 0.91
Exogenous reinfection in experimental airborne tuberculosis. Tubercle (1985) 0.90
Lymphocyte proliferation to mycobacterial antigens is detectable across a spectrum of HIV-associated tuberculosis. BMC Infect Dis (2009) 0.87
Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis (2000) 0.84
Reinfection with Mycobacterium tuberculosis. Am J Respir Crit Care Med (2006) 0.84
Endogenous reactivation and true treatment failure as causes of recurrent tuberculosis in a high incidence setting with a low HIV infection. Trop Med Int Health (2007) 0.83
Baseline mycobacterial immune responses in HIV-infected adults primed with bacille Calmette-Guérin during childhood and entering a tuberculosis booster vaccine trial. J Infect Dis (2006) 0.81
Cytokine responses induced by Mycobacterium tuberculosis in patients with HIV-1 infection and tuberculosis. Int J Infect Dis (2005) 0.79
The effects of BCG immunization and human immunodeficiency virus infection on dual skin test reactions to purified protein derivative and Mycobacterium avium sensitin among adults in Zambia. Int J Tuberc Lung Dis (1999) 0.78
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med (2011) 6.14
Tuberculosis. N Engl J Med (2013) 4.75
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis (2005) 4.45
Endothelial function in HIV-infected persons. Clin Infect Dis (2006) 3.80
Predictors of acute complications in children with type 1 diabetes. JAMA (2002) 3.04
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A (2005) 2.57
Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania. AIDS (2004) 2.45
Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis (2012) 2.38
Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med (2011) 2.36
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med (2006) 2.33
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol (2005) 2.19
HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr (2005) 2.13
Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis (2011) 2.07
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Early fluid resuscitation reduces morbidity among patients with acute pancreatitis. Clin Gastroenterol Hepatol (2011) 1.88
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis (2008) 1.77
Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS (2010) 1.76
Mortality in sickle cell anemia in Africa: a prospective cohort study in Tanzania. PLoS One (2011) 1.71
Influence of sports, physical education, and active commuting to school on adolescent weight status. Pediatrics (2012) 1.70
Revisiting rates of reactivation tuberculosis: a population-based approach. Am J Respir Crit Care Med (2010) 1.69
Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol (2010) 1.56
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine (2006) 1.48
Use of a population-based survey to describe the health of Boston public housing residents. Am J Public Health (2007) 1.47
Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med (2006) 1.45
The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS (2012) 1.40
Malaria in patients with sickle cell anemia: burden, risk factors, and outcome at the outpatient clinic and during hospitalization. Blood (2009) 1.40
Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine (2011) 1.37
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis (2013) 1.37
Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine (2005) 1.37
The Southern African Centre for infectious disease surveillance: a one health consortium. Emerg Health Threats J (2013) 1.35
The associations of binge alcohol use with HIV/STI risk and diagnosis among heterosexual African American men. Drug Alcohol Depend (2008) 1.33
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine (2005) 1.33
Environmental risk factors for infection with Mycobacterium avium complex. Am J Epidemiol (2006) 1.31
Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS (2003) 1.28
Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup. Am J Epidemiol (2013) 1.27
Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS One (2012) 1.26
Treatment of Tuberculosis. N Engl J Med (2015) 1.25
Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS (2008) 1.25
Utilization of screening mammography in New Hampshire: a population-based assessment. Cancer (2005) 1.19
New vaccines for the prevention of tuberculosis. Clin Infect Dis (2002) 1.15
A first insight into the genetic diversity of Mycobacterium tuberculosis in Dar es Salaam, Tanzania, assessed by spoligotyping. BMC Microbiol (2006) 1.15
Integration of a participatory research strategy into a rural health survey. J Gen Intern Med (2003) 1.14
A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis (2002) 1.14
Basis for treatment of tuberculosis among HIV-infected patients in Tanzania: the role of chest x-ray and sputum culture. BMC Infect Dis (2008) 1.14
Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. BMC Public Health (2008) 1.14
Human immunodeficiency virus infection in a rural community in the United States. Am J Epidemiol (2004) 1.12
Blood culture contamination in Tanzania, Malawi, and the United States: a microbiological tale of three cities. J Clin Microbiol (2006) 1.12
Diabetes, glycemic control, and risk of tuberculosis: a population-based case-control study. Diabetes Care (2011) 1.11
Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis (2004) 1.11
History of incarceration and gang involvement are associated with recent sexually transmitted disease/HIV diagnosis in African American men. J Acquir Immune Defic Syndr (2008) 1.09
The bacteraemia of disseminated tuberculosis among HIV-infected patients with prolonged fever in Tanzania. Scand J Infect Dis (2011) 1.07
Hepatitis A, B and C viral co-infections among HIV-infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health (2008) 1.05
Antimicrobial resistance in human and animal pathogens in Zambia, Democratic Republic of Congo, Mozambique and Tanzania: an urgent need of a sustainable surveillance system. Ann Clin Microbiol Antimicrob (2013) 1.03
Tuberculosis in HIV voluntary counselling and testing centres in Dar es Salaam, Tanzania. Scand J Infect Dis (2010) 1.01
Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis (2013) 1.00
Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis (2003) 1.00
The perceptions on male circumcision as a preventive measure against HIV infection and considerations in scaling up of the services: a qualitative study among police officers in Dar es Salaam, Tanzania. BMC Public Health (2012) 0.99
Risk of progression to active tuberculosis among foreign-born persons with latent tuberculosis. Chest (2007) 0.99
Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine (2010) 0.99
Balancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania. BMC Public Health (2010) 0.98
Fecal calprotectin concentrations are higher in exclusively breastfed infants compared to those who are mixed-fed. Breastfeed Med (2008) 0.98
Semen protects CD4+ target cells from HIV infection but promotes the preferential transmission of R5 tropic HIV. J Immunol (2010) 0.97
Prevalence of food and beverage brands in movies: 1996-2005. Pediatrics (2010) 0.97
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS One (2012) 0.97
Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: a randomized, controlled trial. AIDS (2003) 0.97
Predictors of failure to complete treatment for latent tuberculosis infection. J Infect (2006) 0.96
Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study. J Acquir Immune Defic Syndr (2014) 0.95